FDA
-
-
-
-
-
-
-
Achillion Pharma (ACHN) Reports Clearance of Investigational New Drug Application for ACH-5228
-
-
-
-
-
-
-
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria
-
-
-
-
-
-
-
Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
-
-
-
-
-
-
-
Achillion Pharma (ACHN) Highlights Positive Interim Data for ACH-4471 Phase 2 Trials; Provides Clinical Development Strategy Update
-
-
-
-
-
-
-
Pre-Open Movers 11/15: (SORL) (CARG) (BCEI) Higher; (ACOR) (VERI) (MTSI) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/28: (LIVE) (GALE) (OCRX) Higher; (ANTH) (QCOM) Lower (more...)
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

